
Argatroban Monohydrate
CAS No. 141396-28-3
Argatroban Monohydrate( —— )
Catalog No. M22735 CAS No. 141396-28-3
Argatroban Monohydrate is a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 30 | In Stock |
![]() ![]() |
10MG | 41 | In Stock |
![]() ![]() |
25MG | 61 | In Stock |
![]() ![]() |
50MG | 91 | In Stock |
![]() ![]() |
100MG | 146 | In Stock |
![]() ![]() |
200MG | 210 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameArgatroban Monohydrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionArgatroban Monohydrate is a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi.
-
DescriptionArgatroban Monohydrate is a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi.(In Vitro):Argatroban (MD-805) may have a complementary effect for preventing thrombus formation without aggravating bleeding tendency because of its monotarget specificity to thrombin. Administration (0.5 to 2 micrograms/kg/min) of Argatroban (MD-805) is a safe anticoagulant for left heart bypass in repairs of traumatic aortic rupture associated with multiple organ injuries. Argatroban (MD-805), as compared with heparin, appears to enhance reperfusion with TPA in patients with AMI, particularly in those patients with delayed presentation. The incidences of major bleeding and adverse clinical outcome were lower in the patients receiving argatroban.
-
In VitroArgatroban (MD-805) may have a complementary effect for preventing thrombus formation without aggravating bleeding tendency because of its monotarget specificity to thrombin. Administration (0.5 to 2 micrograms/kg/min) of Argatroban (MD-805) is a safe anticoagulant for left heart bypass in repairs of traumatic aortic rupture associated with multiple organ injuries. Argatroban (MD-805), as compared with heparin, appears to enhance reperfusion with TPA in patients with AMI, particularly in those patients with delayed presentation. The incidences of major bleeding and adverse clinical outcome were lower in the patients receiving argatroban.
-
In Vivo——
-
Synonyms——
-
PathwayAutophagy
-
TargetThrombin
-
RecptorThrombin
-
Research AreaCardiovascular system
-
IndicationHeparin-Induced Thrombocytopenia
Chemical Information
-
CAS Number141396-28-3
-
Formula Weight526.65
-
Molecular FormulaC23H38N6O6S
-
Purity>98% (HPLC)
-
SolubilityDMSO:99 mg/mL(187.98 mM)
-
SMILESO.C[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)c1cccc2CC(C)CNc12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Berry CN, et al. Br J Pharmacol,1994, 113(4), 1209-1214.
molnova catalog



related products
-
Eltrombopag
Eltrombopag is an orally active thrombopoietin receptor agonist with megakaryopoiesis stimulating activity.
-
Imitrodast
Imitrodast is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor for the treatment of immune system disorders, respiratory disorders, and cardiovascular diseases, and can be used in studies of arterial thrombosis, asthma, and coronary vasospasm.
-
Etamsylate
Ethamsylate is a haemostatic drug, which inhibits biosynthesis and action of prostaglandins, and increases capillary endothelial resistance as and platelet adhesion.